Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Recent & Breaking News (TSXV:CLAS.H)

First Asset ETFs September Distributions

Canada NewsWire September 19, 2017

Kalytera Receives IRB Approval for Proposed Phase 2 Study Evaluating CBD in the Prevention of Graft versus Host Disease

GlobeNewswire September 7, 2017

Kalytera Reports Second Quarter 2017 Financial Results

GlobeNewswire August 31, 2017

Kagan Releases Second Quarter U.S. Multichannel Subscriber Report

PR Newswire August 15, 2017

S&P/Experian Consumer Credit Default Indices Show The Composite Default Rate Remained Low In July 2017

PR Newswire August 15, 2017

Kalytera Submits Phase 2 Study Protocol to IRBs for Cannabidiol in the Prevention of Graft versus Host Disease

GlobeNewswire August 14, 2017

Kalytera Announces Management Changes and Expansion of Leadership Team

GlobeNewswire June 22, 2017

First Asset ETFs June Distributions

Canada NewsWire June 20, 2017

First Asset ETFs March Distributions

Canada NewsWire March 21, 2017

Kalytera Therapeutics, Inc. (formerly Santa Maria Petroleum Inc.) Announces Filing of Filing Statement

MarketWire Canada December 30, 2016

First Asset ETFs December Distributions

Canada NewsWire December 16, 2016

Santa Maria Petroleum Inc. and Kalytera Therapeutics, Inc. Provide Update Regarding Proposed Merger

MarketWire Canada November 29, 2016

Santa Maria Petroleum Inc. Announces Third Quarter 2016 Results

MarketWire Canada November 8, 2016

Santa Maria Petroleum Inc. and Kalytera Therapeutics, Inc. Announce Signing of Merger Agreement and Closing of Concurrent Subscription Receipt Financing

MarketWire Canada November 4, 2016

IIROC Trading Halt - SMQ.H

Canada NewsWire October 7, 2016

IIROC Trade Halt - Santa Maria Petroleum Inc.

Newsfile October 7, 2016

Santa Maria Announces Letter of Intent for Proposed Merger With Kalytera Therapeutics

MarketWire Canada October 6, 2016

Santa Maria Petroleum Inc. Announces Closing of Private Placement

MarketWire Canada September 23, 2016

First Asset ETFs September Distributions

Canada NewsWire September 20, 2016

Santa Maria Petroleum Inc. Announces Second Quarter 2016 Results

MarketWire Canada August 26, 2016